Page last updated: 2024-11-02

piracetam and Cirrhosis, Liver

piracetam has been researched along with Cirrhosis, Liver in 1 studies

Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.

Research Excerpts

ExcerptRelevanceReference
"The predicted versus observed plasma concentration-time profiles for alfentanil and lidocaine were similar, such that the pharmacokinetic changes associated with Child-Pugh class A, B and C liver cirrhosis were adequately described."3.74Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. ( Edginton, AN; Willmann, S, 2008)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Edginton, AN1
Willmann, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sugammadex Versus Neostigmine for Antagonism of Rocuronium-induced Neuromuscular Blockade in Patients With Liver Cirrhosis Undergoing Liver Resection: A Controlled Randomized Study[NCT02414880]Phase 460 participants (Actual)Interventional2014-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for piracetam and Cirrhosis, Liver

ArticleYear
Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
    Clinical pharmacokinetics, 2008, Volume: 47, Issue:11

    Topics: Alfentanil; Humans; Levetiracetam; Lidocaine; Liver Cirrhosis; Models, Biological; Piracetam; Theoph

2008